The funding will help several initiatives including patient follow-up with trials, opening a research and development center in Dallas and completing a facility in Geneva, Switzerland, according to a news release.
The company completed enrollment for the U.S. investigational device exemption trial with the Baguera C cervical disc implant, according to a Feb. 29 announcement. The trial will compare Baguera C in single-level cervical disc replacement to ZimVie’s Mobi-C.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
